FDA withdraws approval for premature birth drug

The Food and Drug Administration today withdrew approval for Makena and its generics, citing a confirmatory study that did not verify clinical benefit. Makena had been approved under the FDA’s accelerated approval pathway to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. Makena and its generics cannot lawfully be distributed in interstate commerce, effective immediately. FDA is aware that some products have already been distributed, so health care providers should talk to their patients, if applicable.
Related News Articles
Headline
Nearly 57% of mothers did not attend a postpartum follow-up visit three to eight weeks after giving birth, according to a report published July 29 by Cedar…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The Joint Commission July 29 announced an initiative to address “gaps” in how children’s hospitals are accredited and certified. The program will remove or…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
A Health Affairs study on the decline of obstetric services in rural and urban hospitals nationwide from 2010-2022 found that seven states had at least 25% of…
Headline
The Food and Drug Administration has issued early alerts for certain Spectrum infusion pumps from Baxter and Abiomed Automated Impella Controllers. The agency…